Anti-Human/Mouse Mac-2 (Galectin-3) (Clone M3/38 ) – Purified No Carrier Protein

Anti-Human/Mouse Mac-2 (Galectin-3) (Clone M3/38 ) – Purified No Carrier Protein

Product No.: M360

- -
- -
Clone
M3/38
Target
Mac-2 (Galectin-3)
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
Gal-3, RL-29, galactose-specific lectin 3, CBP-35, L-34
Isotype
Rat IgG2a κ
Applications
ELISA
,
FC
,
IF
,
IHC
,
IP
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human/Mouse
Host Species
Rat
Immunogen
Raised against galectin-3 of mouse origin
Product Concentration
0.5 mg/ml
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
State of Matter
Liquid
Storage and Handling
This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Additional Applications Reported In Literature ?
ELISA,
FC,
IF,
IHC,
IP,
WB
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
M3/38 activity is directed against human and mouse Mac-2 (Galectin-3).
Background
Mac-2 (Galectin-3) is a β-galactoside-binding lectin of the chimera-type, characterized by a single carbohydrate recognition domain and an N-terminal polypeptide tail region1. Mac-2 plays important roles in cell proliferation, apoptotic regulation, cell-to-cell and cell-to-matrix interactions, macrophage activation, angiogenesis, inflammation, fibrosis and host defense. Additionally, Mac-2 is an early-stage diagnostic and/or prognostic biomarker for viral infection, neurodegenerative disorders, tumor formation, diabetes mellitus, and certain types of heart, kidney, and autoimmune disease. The primary structure of mouse and human Mac-2 is highly conserved with 85% similarity2. Human Mac-2 binds to asialofetuin and purified laminin.

M3/38 was generated by immunizing rats with immunoadsorbent-purified macrophage glycoproteins and fusing the resulting spleen cells with mouse myeloma cells3. M3/38 is able to immunoprecipitate both the mouse and human Mac-2 homologs2,3. M3/38 binding to Mac-2 can be inhibited by galactose2. M3/38 recognizes a linear epitope within the N-terminal domain of Mac-24. The common minimal sequence as determined by SPOT analysis as Ala-Pro-Pro-Gly-Ala-Tyr.

M3/38 has been exploited for live cell thyroid tumor imaging4,5. A chimeric M3/38 Fab-fragment and its humanized derivative can detect Mac-2 overexpression in cancerous thyroid nodules in mice via positron emission tomography. The three-dimensional structure of the rat/human chimeric Fab has been determined5.
Antigen Distribution
Mac-2 (Galectin-3) is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. Mac-2 is secreted into fluids such as serum and urine as well as released by injured and inflammatory cells. Mac-2 was originally identified in murine inflammatory macrophages. Mac-2 is also expressed by various cell lines (e.g., HeLa, SL68, HL60, HT29).
NCBI Gene Bank ID
UniProt.org
Research Area
Cell Biology
.
Immunology

References & Citations

1 Hara A, Niwa M, Noguchi K, et al. Biomolecules. 10(3):389. 2020.
2 Cherayil BJ, Chaitovitz S, Wong C, et al. Proc Natl Acad Sci U S A. 87(18):7324-7328. 1990.
3 Ho MK, Springer TA. J Immunol. 128(3):1221-1228. 1982.
4 Peplau E, De Rose F, Eichinger A, et al. Sci Rep. 11(1):7358. 2021.
5 Peplau E, De Rose F, Reder S, et al. Thyroid. 30(9):1314-1326. 2020.
6 Flotte TJ, Springer TA, Thorbecke GJ. Am J Pathol. 111(1):112-24. 1983.
7 Nibbering PH, Leijh PC, van Furth R. Cell Immunol. 105(2):374-385. 1987.
8 Nibbering PH, Leijh PC, van Furth R. Immunology. 62(2):171-176. 1987.
9 Nibbering PH, van Furth R. Immunobiology. 176(4-5):432-439. 1988.
10 Nibbering PH, van der Heide A, van Furth R. J Pathol. 157(3):253-261. 1989.
11 Toussaint-Demylle D, Many MC, Theisen H, et al. Autoimmunity. 7(1):51-62. 1990.
12 Knisley KA, Weitlauf HM. J Reprod Fertil. 97(2):521-527. 1993.
13 Dumić J, Lauc G, Hadzija M, et al. Z Naturforsch C J Biosci. 55(3-4):261-266. 2000.
14 Mey A, Berthier-Vergnes O, Apoil PA, et al. Cancer Lett. 81(2):155-163. 1994.
15 Nachtigal M, Al-Assaad Z, Mayer EP, et al. Am J Pathol. 152(5):1199-1208. 1998.
16 Piantelli M, Iacobelli S, Almadori G, et al. J Clin Oncol. 20(18):3850-3856. 2002.
17 Schaffert C, Pour PM, Chaney WG. Int J Pancreatol. 23(1):1-9. 1998.
18 Dumic J, Lauc G, Flögel M. Cell Physiol Biochem. 10(3):149-158. 2000.
19 Dumić J, Barisić K, Flögel M, et al. Stress. 3(3):241-246. 2000.
20 Mey A, Leffler H, Hmama Z, et al. J Immunol. 156(4):1572-1577. 1996.
Indirect Elisa Protocol
Flow Cytometry
IF
IHC
Immunoprecipitation Protocol
General Western Blot Protocol

Certificate of Analysis

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.